— Know what they know.
Not Investment Advice

ZVSA OTC

ZyVersa Therapeutics, Inc.
1W: -19.2% 1M: -19.4% 3M: -48.1% YTD: -40.7% 1Y: -44.1% 3Y: -99.8%
$0.08
+0.00 (+0.00%)
 
Weekly Expected Move ±16.8%
$0 $0 $0 $0 $0
OTC · Healthcare · Biotechnology · Tech Score Sell · Power 36 · $647674 mcap · 5M float · 0.217% daily turnover · Short 31% of daily vol

Balance Sheet Trends

Total Assets
$21M -6.9% ▼
4Y CAGR: +134.1%
Total Liabilities
$12M +9.5% ▲
4Y CAGR: +6.9%
Shareholders Equity
$9M -23.1% ▼
Cash & Investments
$2M -51.2% ▼
4Y CAGR: +72.1%
Total Debt
$0 -100.0% ▼
Net Debt
-$2M +51.1% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2020FY2021FY2022FY2023FY2024
— Assets —
Cash$175K$329K$6M$3M$2M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$175K$329K$6M$3M$2M
Net Receivables$0$0$0$0$0
Inventory$0$0$0$0$0
Other Current Assets$164K$483K$460K$215K$185K
Total Current Assets$339K$812K$6M$3M$2M
Property, Plant & Equip.$38K$28K$116K$15K$0
Goodwill & Intangibles$0$0$112M$19M$19M
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$308K$287K$47K$98K$236K
Total Non-Current Assets$346K$314K$112M$19M$19M
Total Assets$686K$1M$119M$22M$21M
— Liabilities —
Accounts Payable$2M$2M$6M$8M$9M
Short-Term Debt$2M$9M$109K$9K$0
Deferred Revenue$21K$17K$0$0$0
Other Current Liabilities$2M$2M$1M$1M$855K
Total Current Liabilities$8M$14M$8M$10M$11M
Long-Term Debt$2M$0$0$0$0
Other Non-Current Liab.$0$0$0$0$0
Total Non-Current Liabilities$2M$0$10M$845K$852K
Total Liabilities$9M$14M$19M$11M$12M
— Equity —
Common Stock$242$242$902$405$251
Retained Earnings-$45M-$53M-$5M-$103M-$113M
Accumulated OCI$0$0$0$0$0
Total Stockholders Equity-$9M-$13M$100M$11M$9M
Total Liabilities & Equity$686K$1M$119M$22M$21M
— Key Metrics —
Total Debt$4M$9M$109K$9K$0
Net Debt$4M$9M-$6M-$3M-$2M
Total Investments$0$0$0$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms